Written by the Nuvirox Research Team
- Five clinical studies — including one 3-month, 1,800-volunteer multicenter trial — have found positive signals for topical melatonin in androgenetic alopecia (male and female pattern hair loss), with good tolerability across all studies.
- A 2004 RCT (the strongest design in the set) found topically applied 0.1% melatonin solution significantly increased anagen (growth phase) hair rate in women with androgenetic alopecia at the occipital area vs. placebo.
- Topical melatonin applied to the scalp does not significantly raise serum melatonin levels, meaning it is unlikely to affect sleep — it's a separate application from oral melatonin supplementation.
Short answer: topical melatonin is a biologically distinct use case from oral melatonin — it's applied to the scalp for hair growth support, not taken orally for sleep. The human evidence is cautiously positive for androgenetic alopecia (pattern hair loss in both men and women), with five published clinical studies all showing favorable outcomes and good tolerability. The evidence base is smaller and less rigorous than the oral melatonin sleep literature, but the signals are real enough that several dermatology researchers consider it a legitimate option. The FDA has not approved topical melatonin for hair loss; it's available as a cosmetic product in many markets.
What is topical melatonin and how is it different from oral melatonin?
When melatonin is applied to the skin or scalp — typically as a 0.1% solution or lotion — it acts locally through melatonin receptors in hair follicle cells rather than entering the bloodstream in meaningful amounts. The hair follicle is now understood to be a complete peripheral melatonin system: it has the enzymes to synthesize melatonin locally, melatonin receptors (MT1 and MT2), and responds to melatonin's antioxidant and anti-inflammatory properties. This is why topical melatonin's primary application is dermatological rather than sleep-related.
The pharmacodynamic studies confirm this separation: topical application of a 0.1% melatonin solution in the evening does not produce a significant increase in serum melatonin levels. It stays local. This means people using topical melatonin for hair loss don't need to worry about disrupting their sleep-wake cycle, and people using oral melatonin for sleep are targeting an entirely different mechanism.
Hair cycle phases are schematic. The proposed mechanism for topical melatonin is anagen phase extension and telogen reduction; the exact signaling pathway in humans is not fully established.
What human studies actually show about topical melatonin
Fischer et al. (2004) — British Journal of Dermatology (PMID: 14996107, DOI: 10.1111/j.1365-2133.2004.05685.x): The strongest design in the topical melatonin hair literature. A double-blind, randomized, placebo-controlled trial in 40 women with androgenetic or diffuse alopecia. A 0.1% melatonin solution was applied to the scalp once daily for 6 months; trichograms assessed anagen and telogen hair rates. Result: topical melatonin significantly increased anagen hair rate in occipital hair in women with androgenetic alopecia vs. placebo (n=12, p=0.012). In the diffuse alopecia group, frontal hair showed a significant anagen increase (p=0.046). Plasma melatonin levels increased slightly under treatment but did not exceed the physiological night peak — confirming the local rather than systemic mechanism. The mode of action was not established.
Fischer et al. (2012) — International Journal of Trichology (PMID: 23766606): A broader review compiling five clinical studies using a commercial 0.1% topical melatonin cosmetic solution. Findings across studies: (1) pharmacodynamic study confirming no significant influence on endogenous serum melatonin levels; (2) observational study in 30 men and women showing significant reduction in alopecia severity at 30 and 90 days (p<0.001); (3) in 35 women applying melatonin to the occipital area, an 8.7% increase in anagen hairs vs. 3.9% with placebo; (4) in 60 men and women, significant hair loss reduction observed in women while men remained constant (p<0.001); (5) a large multicenter, 3-month study in more than 1,800 volunteers at 200 centers — the percentage with a 2-to-3-fold positive hair-pull test dropped from 61.6% to 7.8%, while negative hair-pull tests rose from 12.2% to 61.5% (p<0.001). All five studies reported good tolerability.
The honest counterweight — Babadjouni et al. 2023 systematic review (Healio Dermatology): A review of the melatonin and hair growth literature through 2022 found 8 studies showing positive outcomes for androgenetic alopecia, 8 studies showing scalp hair growth improvement, 4 showing density improvement, and 2 showing shaft thickness benefit. The authors noted that evidence supports melatonin use for scalp hair growth "particularly in men with AGA" — but also flagged that the optimal dose range (0.0033% or 0.1%) and duration (90–180 days) remain empirical rather than derived from dose-finding RCTs. The evidence base, while consistently positive, lacks the large-scale, independently funded, placebo-controlled RCTs that would make a definitive recommendation possible.
How topical melatonin compares to existing hair loss treatments
FDA-approved treatments for androgenetic alopecia are topical minoxidil (for men and women) and oral finasteride (for men). These have substantial clinical trial backing but also known side effects: minoxidil can cause scalp irritation and rarely systemic effects; finasteride carries sexual side effect risk and is contraindicated in women who could become pregnant. Topical melatonin has a very favorable tolerability profile across all published studies and presents no known systemic risk at topical doses. It is not, however, an approved treatment — it's a cosmetic ingredient in most regulatory frameworks, and the effect sizes in the available trials, while positive, are more modest than what's demonstrated for minoxidil at 1-year endpoints.
What topical melatonin won't do
It won't reverse advanced hair loss with scarring or long-dormant follicles. It won't substitute for an evaluation of the underlying cause of hair loss — which in women especially can include iron deficiency, thyroid dysfunction, or telogen effluvium from a specific stressor, all of which respond to different interventions. Topical melatonin's evidence is specifically in androgenetic (hormone-driven, genetic pattern) and diffuse alopecia, not in alopecia areata (autoimmune) or scarring alopecias.
See a dermatologist if you're experiencing rapid or patchy hair loss, if the loss started suddenly in conjunction with a health change, or if you're considering topical melatonin alongside other active hair loss treatments. Combining with minoxidil hasn't been studied in large trials.
How to use topical melatonin for hair loss
The protocol used across the published clinical studies is a 0.1% melatonin solution applied to the scalp once daily in the evening. Duration in the most informative trials was 90–180 days. Applying in the evening is consistent with melatonin's circadian biology — the hair follicle appears responsive to the evening melatonin signal — though whether timing relative to darkness matters specifically for topical scalp application hasn't been formally tested. Nanostructured lipid carrier formulations, which may improve local skin penetration, are being explored in newer research but lack the clinical track record of the standard 0.1% solution used in the published trials.
Frequently asked questions
Can I use oral melatonin supplements for hair loss instead?
The evidence is specifically for topical application; there are no published RCTs showing oral melatonin supplementation promotes hair growth. The hair follicle mechanism appears to operate through local melatonin signaling, not systemic blood levels, which is why topical application shows effects while oral use doesn't raise scalp-tissue melatonin concentrations in the same targeted way.
Will topical melatonin make me sleepy?
Based on the pharmacodynamic data from the Fischer trials — where plasma melatonin levels remained within the physiological night peak range — topical scalp application at 0.1% should not produce sedation. The systemic absorption is low enough that meaningful circadian disruption is unlikely.
How long does it take for topical melatonin to work for hair loss?
The published studies showing significant effects used 90–180-day treatment periods. Hair cycle dynamics are slow — an anagen phase lasts 2–6 years; meaningful change in anagen:telogen ratio takes months to manifest as visible hair density change. Don't expect visible results in less than 12 weeks.
Is topical melatonin available in the United States?
Topical melatonin hair serums are available in the US as cosmetic products. They're not FDA-approved for hair loss. Concentrations vary; products at 0.1% melatonin match the clinical trial formulation most closely. Check the ingredient list for the concentration, as some products use much lower amounts.
Does topical melatonin work for men as well as women?
The Fischer 2012 review found the strongest effects in women (significant hair loss reduction) and noted that hair loss in men "remained constant" in one study — meaning stabilization rather than regrowth was the observed male outcome. The 2023 Babadjouni systematic review concluded evidence is particularly supportive for men with AGA. The disparity may reflect the different androgen sensitivity patterns in male vs. female androgenetic alopecia rather than a fundamental difference in topical melatonin mechanism.
FROM NUVIROX
If sleep is your goal: Sleep+ Restore
If you arrived here looking for sleep support rather than hair loss, Sleep+ Restore is Nuvirox's oral sleep formula — 10 mg melatonin plus a 905 mg proprietary blend of L-Theanine, GABA, Ashwagandha, 5-HTP, Chamomile, Lemon Balm, Passion Flower, and more, alongside Vitamin B6 (1.8 mg, 106% DV). It's formulated for systemic sleep support through multiple pathways, not scalp application.*
Learn more about Sleep+ Restore →The bottom line
Topical melatonin is one of the more intriguing areas in hair loss research, with five clinical studies consistently showing positive signals and excellent tolerability. The 0.1% solution applied to the scalp once daily for 90–180 days is the most evidence-supported protocol. The evidence base is smaller and lacks the large independently funded RCTs that would make a clinical recommendation straightforward, but the safety profile is favorable and the mechanism — local melatonin receptor signaling in hair follicles — is biologically coherent. It's a reasonable adjunct to explore for pattern hair loss, ideally alongside a dermatologist evaluation of your specific hair loss type. If oral melatonin for sleep is what you're researching instead, the overlap with topical application is minimal — for that, the melatonin evidence overview and our guide on how much melatonin to take for sleep are the relevant starting points.
References
- Fischer TW, Burmeister G, Schmidt HW, Elsner P. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. Br J Dermatol. 2004;150(2):341-345. PMID: 14996107. DOI: 10.1111/j.1365-2133.2004.05685.x.
- Fischer TW, Fischer A, Knöll B, et al. Topical melatonin for treatment of androgenetic alopecia. Int J Trichology. 2012;4(4):236-245. PMID: 23766606.
- Babadjouni A, et al. Topical melatonin improves scalp hair growth, density in androgenetic alopecia. Healio Dermatology. 2023. Review covering PubMed, Google Scholar, Cochrane databases through 2022.
- Bald A, et al. Clinical studies using topical melatonin. Int J Mol Sci. 2024;25(10):5167. DOI: 10.3390/ijms25105167.
- Cruz-Sanabria F, et al. Optimizing the time and dose of melatonin as a sleep-promoting drug. J Pineal Res. 2024;76:e12985. DOI: 10.1111/jpi.12985.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.